NVO, VKTX Stocks Fall as Lilly's Zepbound, Mounjaro Sales Slow Down
Portfolio Pulse from
Shares of obesity drugmakers, including NVO and VKTX, fell after Eli Lilly (LLY) lowered its revenue outlook for 2024 due to slower-than-expected sales growth of its tirzepatide products, Zepbound and Mounjaro, in Q4.
January 15, 2025 | 7:45 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
LLY's stock is likely to be negatively impacted due to the lowered revenue outlook for 2024, driven by slower sales growth of its tirzepatide products.
LLY's announcement of a reduced revenue outlook directly affects its stock price as it indicates slower-than-expected sales growth of key products, impacting investor sentiment.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
NVO shares fell as Eli Lilly's reduced revenue outlook for 2024 impacted the market perception of obesity drugmakers.
NVO is affected by the broader market sentiment towards obesity drugmakers following LLY's announcement. The reduced revenue outlook for LLY's tirzepatide products suggests potential challenges in the obesity drug market, impacting NVO's stock.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
NEGATIVE IMPACT
VKTX shares declined as part of a broader sell-off in obesity drugmakers following LLY's announcement of slower sales growth.
VKTX is indirectly impacted by LLY's announcement as it is part of the same sector. The news suggests potential market challenges, leading to a decline in VKTX's stock.
CONFIDENCE 75
IMPORTANCE 50
RELEVANCE 60